secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zenas BioPharma, Inc. (ZBIO)
CIK:        0001953926
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116346
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zenas Q3 2024: Net loss $38.6M; raised $258.7M IPO; obexelimab INDIGO topline by end 2025
--------------------------------------------------------------------------------

- Completed IPO raising $258.7M gross proceeds; cash $386.8M to fund into Q4 2026.
- Phase 3 INDIGO (IgG4-RD) completed enrollment; topline results expected by end 2025.
- Initiated Phase 2 MoonStone (RMS) and SunStone (SLE); MoonStone results Q3 2025, SunStone topline H1 2026.
- Net loss $38.6M vs net income $35.6M (prior year had BMS collaboration); R&D $33.5M vs $9.4M.
- Appointed CCO Orlando Oliveira and CLO Jeff Held; out-licensed ZB005 for upfront and milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1953926/000110465924116346/0001104659-24-116346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1953926/000110465924116346/tm2427736d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer